全文获取类型
收费全文 | 907篇 |
免费 | 86篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 37篇 |
妇产科学 | 38篇 |
基础医学 | 104篇 |
口腔科学 | 20篇 |
临床医学 | 115篇 |
内科学 | 170篇 |
皮肤病学 | 23篇 |
神经病学 | 11篇 |
特种医学 | 143篇 |
外科学 | 95篇 |
综合类 | 20篇 |
预防医学 | 112篇 |
眼科学 | 15篇 |
药学 | 37篇 |
肿瘤学 | 65篇 |
出版年
2023年 | 7篇 |
2021年 | 21篇 |
2020年 | 11篇 |
2019年 | 20篇 |
2018年 | 23篇 |
2017年 | 21篇 |
2016年 | 18篇 |
2015年 | 30篇 |
2014年 | 16篇 |
2013年 | 47篇 |
2012年 | 38篇 |
2011年 | 45篇 |
2010年 | 33篇 |
2009年 | 35篇 |
2008年 | 25篇 |
2007年 | 44篇 |
2006年 | 27篇 |
2005年 | 15篇 |
2004年 | 11篇 |
2003年 | 16篇 |
2002年 | 19篇 |
2001年 | 18篇 |
2000年 | 10篇 |
1999年 | 21篇 |
1998年 | 62篇 |
1997年 | 55篇 |
1996年 | 27篇 |
1995年 | 31篇 |
1994年 | 15篇 |
1993年 | 16篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 16篇 |
1989年 | 13篇 |
1988年 | 13篇 |
1987年 | 21篇 |
1986年 | 12篇 |
1985年 | 14篇 |
1984年 | 12篇 |
1983年 | 10篇 |
1982年 | 13篇 |
1981年 | 6篇 |
1980年 | 13篇 |
1978年 | 4篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 9篇 |
1972年 | 4篇 |
1970年 | 4篇 |
1969年 | 6篇 |
排序方式: 共有1007条查询结果,搜索用时 15 毫秒
991.
Gnjidic D Le Couteur DG Naganathan V Cumming RG Creasey H Waite LM Sharma A Blyth FM Hilmer SN 《Journal of clinical psychopharmacology》2012,32(2):273-277
We aimed to assess the relationship between Drug Burden Index (DBI), a risk assessment tool that measures anticholinergic and sedative medication exposure and cognitive performance, and cognitive impairment in older people. The study population consisted of community-dwelling older men, 70 years or older, living in Sydney, Australia. The Addenbrooke's Cognitive Examination (ACE) and the Trail Making Task (TMT) cognitive tests were performed, and participants were categorized as having intact cognition, mild cognitive impairment, or dementia using clinical diagnostic criteria. The analyses were restricted to participants with English-speaking background (n = 987) and to the subgroup whose cognition was intact (n = 887). In the study group, DBI exposure was not associated with poorer performance on the ACE (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.66-1.47) or the TMT (OR, 0.71; 95% CI, 0.40-1.24) tests, after controlling for covariates. Similarly, DBI exposure was not associated with cognitive impairment (OR, 1.34; 95% CI, 0.83-2.16). There was no association between increasing DBI scores and poorer performance on any of the outcomes. On subgroup analysis of cognitively intact subgroup, DBI exposure or increasing DBI scores were not associated with poorer performance on the ACE or the TMT tests. In this study of community-dwelling older men, DBI was not associated with limitations on objective cognitive performance measures or with a clinical diagnosis of mild cognitive impairment or dementia. 相似文献
992.
993.
Aim: To review the use of antifungal chemoprophylaxis to prevent neonatal invasive fungal infections (IFI) in very low birthweight infants (VLBW <1500 g). Method: Systematic review of randomised controlled trials. Results: Nine trials were identified (2029 infants), with six comparing fluconazole with placebo/no treatment (840 infants), three comparing nystatin with placebo/no treatment (1200 infants) and two comparing fluconazole and nystatin (257 infants). Prophylactic fluconazole reduced the incidence of IFI in VLBW infants <1500 g to 5.1% compared with 16.0% in infants receiving placebo, relative risk (RR) = 0.36 (95% confidence interval 0.15–0.89). The mortality was 10.9% and 16.7%, respectively (RR 0.76, 0.54–1.08). Oral nystatin reduced the incidence of IFI in VLBW infants to 5.3% compared with 28.0% in infants receiving placebo (RR 0.16, 0.11–0.23). Mortality was 7.5% with nystatin and 10.9% with placebo (RR 0.86, 0.59–1.26). The incidence of IFI in studies comparing fluconazole and nystatin was 3.6% and 8.0%, respectively (RR 0.54, 0.19–1.56), and mortality was not significantly different: 4.6% versus 9.8% (RR 0.43, 0–4.31) Conclusions: Prophylactic fluconazole and oral nystatin are both highly effective in preventing IFI in VLBW infants. Both agents are safe without significant toxicities. Antifungal prophylaxis should therefore be used in all VLBW infants. Given the paucity of data comparing fluconazole with nystatin, the choice of antifungal agent should be influenced by the incidence of IFI, local epidemiology and relative cost. 相似文献
994.
Blyth CC Currie AJ Wiertsema SP Conway N Kirkham LA Fuery A Mascaro F Geelhoed GC Richmond PC 《Vaccine》2011,29(32):5107-5113
Introduction
Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010. We describe the epidemiology and clinical features of the adverse events and explore the biological basis for the adverse events using an in vitro model.Materials and Methods
Children presenting to a tertiary paediatric hospital in 2010 with adverse events within 72 h of TIV were retrospectively reviewed. Demographics, clinical features, physiological variables and outcomes were examined. Plasma cytokine and chemokine levels were examined in a subgroup of children with vaccine-related febrile convulsions. Peripheral blood mononuclear cells of age-matched children were stimulated with different TIV preparations. Inflammatory cytokine and chemokine analysis was performed on cultured supernatants.Results
Vaccine-related febrile adverse events were identified in 190 children. Most occurred in healthy children (median age: 1.5 years) within 12 h of vaccination. Twenty-eight (14.7%) required hospital admission. High temperature ≥39.0 °C (101/190; 53%), vomiting (120/190; 63%) and convulsions (38/190; 20%) were common. All children presenting had received Fluvax® or Fluvax Junior®.In the in vitro model, IFN-α, IL-1β, IL-6, IL-10, IP-10 and MIP-1α levels were significantly higher when measured at 6 and 24 h in cultures stimulated with Fluvax® compared with alternative 2010 TIV preparations.Conclusions
Numerous febrile adverse events (including febrile seizures) were observed following Fluvax® or Fluvax Junior® in 2010. Clear differences in cytokine production were observed when peripheral blood mononuclear cells were stimulated with Fluvax® compared with alternate TIV preparations. Increased awareness of these potential adverse events is required to ensure earlier detection and prevention in the future. 相似文献995.
996.
997.
Murphy E Spencer SJ Young D Jones B Blyth MJ 《The Journal of bone and joint surgery. British volume》2011,93(4):548-551
The objective of this study was to determine the effectiveness of screening and successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) colonisation in elective orthopaedic patients on the subsequent risk of developing a surgical site infection (SSI) with MRSA. We screened 5933 elective orthopaedic in-patients for MRSA at pre-operative assessment. Of these, 108 (1.8%) were colonised with MRSA and 90 subsequently underwent surgery. Despite effective eradication therapy, six of these (6.7%) had an SSI within one year of surgery. Among these infections, deep sepsis occurred in four cases (4.4%) and superficial infection in two (2.2%). The responsible organism in four of the six cases was MRSA. Further analysis showed that patients undergoing surgery for joint replacement of the lower limb were at significantly increased risk of an SSI if previously colonised with MRSA. We conclude that previously MRSA-colonised patients undergoing elective surgery are at an increased risk of an SSI compared with other elective patients, and that this risk is significant for those undergoing joint replacement of the lower limb. Furthermore, when an infection occurs, it is likely to be due to MRSA. 相似文献
998.
999.
1000.